BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 32112433)

  • 1. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
    Montalban-Bravo G; Kanagal-Shamanna R; Class CA; Sasaki K; Ravandi F; Cortes JE; Daver N; Takahashi K; Short NJ; DiNardo CD; Jabbour E; Borthakur G; Naqvi K; Issa GC; Konopleva M; Khoury JD; Routbort M; Pierce S; Do KA; Bueso-Ramos C; Patel K; Kantarjian H; Garcia-Manero G; Kadia TM
    Am J Hematol; 2020 Jun; 95(6):612-622. PubMed ID: 32112433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome.
    Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Guo R; Tierens A; Minden MD; Chang H
    Hum Pathol; 2020 Oct; 104():117-126. PubMed ID: 32798550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
    Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
    Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
    Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
    Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
    Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
    [No Abstract]   [Full Text] [Related]  

  • 6. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
    Miesner M; Haferlach C; Bacher U; Weiss T; Macijewski K; Kohlmann A; Klein HU; Dugas M; Kern W; Schnittger S; Haferlach T
    Blood; 2010 Oct; 116(15):2742-51. PubMed ID: 20581309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
    Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes.
    Fang H; He R; Chiu A; Viswanatha DS; Ketterling RP; Patnaik MS; Reichard KK
    Am J Clin Pathol; 2020 Apr; 153(5):656-663. PubMed ID: 31977035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
    DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
    Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
    Kim M; Williams S
    Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferential occurrence of spliceosome mutations in acute myeloid leukemia with preceding myelodysplastic syndrome and/or myelodysplasia morphology.
    Cho YU; Jang S; Seo EJ; Park CJ; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH; Koh KN; Im HJ; Seo JJ; Park SH; Park YM; Lee JK
    Leuk Lymphoma; 2015; 56(8):2301-8. PubMed ID: 25487075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Survival and Prognosis of Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes Transformed from Myelodysplastic Syndrome].
    Shang LM; Chen HJ; Liu Y; Cao Y; Li F; Guo YT; Dong WM; Lin Y; Gu WY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):347-354. PubMed ID: 38660835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The new diagnostic criteria for myelodysplasia-related acute myeloid leukemia is useful for predicting clinical outcome: comparison of the 4th and 5th World Health Organization classifications.
    Park HS; Kim HK; Kim HS; Yang Y; Han HS; Lee KH; Son BR; Kwon J
    Ann Hematol; 2022 Dec; 101(12):2645-2654. PubMed ID: 36220882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-lineage level-targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes.
    Yokoyama K; Shimizu E; Yokoyama N; Nakamura S; Kasajima R; Ogawa M; Takei T; Ito M; Kobayashi A; Yamaguchi R; Imoto S; Miyano S; Tojo A
    Blood Adv; 2018 Oct; 2(19):2513-2521. PubMed ID: 30282643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
    Morsia E; McCullough K; Joshi M; Cook J; Alkhateeb HB; Al-Kali A; Begna K; Elliott M; Hogan W; Litzow M; Shah M; Pardanani A; Patnaik M; Tefferi A; Gangat N
    Am J Hematol; 2020 Dec; 95(12):1511-1521. PubMed ID: 32833294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical and Cytogenetical Characteristics in Acute Myeloid Leukemia with Myelodysplasia-Related Changes].
    Ma JL; Zhou AQ; Gu SY; Chen BA; Ge Z
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1757-1762. PubMed ID: 34893106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical and prognostic characteristics of pediatric acute myeloid leukemia with myelodysplasia-related changes under different diagnostic criteria].
    Zhang RR; Ruan M; Liu TF; Wang SC; Zhang XY; Qi BQ; Zhu XF; Zhang L
    Zhonghua Er Ke Za Zhi; 2024 Mar; 62(3):250-255. PubMed ID: 38378287
    [No Abstract]   [Full Text] [Related]  

  • 18. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
    Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
    BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical importance of morphological multilineage dysplasia in acute myeloid leukemia with myelodysplasia related changes].
    Park SH; Chi HS; Park SJ; Jang S; Park CJ
    Korean J Lab Med; 2010 Jun; 30(3):231-8. PubMed ID: 20603581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
    Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.